$1.23 Million in Sales Expected for Mesoblast limited (MESO) This Quarter

Wall Street brokerages expect that Mesoblast limited (NASDAQ:MESO) will announce $1.23 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Mesoblast’s earnings, with estimates ranging from $1.17 million to $1.29 million. Mesoblast reported sales of $1.07 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 15%. The business is scheduled to issue its next earnings results on Thursday, May 30th.

According to Zacks, analysts expect that Mesoblast will report full year sales of $16.05 million for the current fiscal year, with estimates ranging from $15.91 million to $16.18 million. For the next financial year, analysts forecast that the firm will post sales of $10.33 million, with estimates ranging from $9.47 million to $11.18 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Mesoblast.

Mesoblast (NASDAQ:MESO) last issued its earnings results on Wednesday, February 20th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). The firm had revenue of $1.87 million during the quarter, compared to the consensus estimate of $6.36 million. Mesoblast had a negative return on equity of 15.98% and a negative net margin of 528.80%.

Several research firms have commented on MESO. HC Wainwright reissued a “buy” rating on shares of Mesoblast in a report on Friday, February 22nd. TheStreet downgraded shares of Mesoblast from a “c-” rating to a “d+” rating in a report on Monday, December 10th. Zacks Investment Research raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Saturday, February 2nd. Oppenheimer set a $15.00 price objective on shares of Mesoblast and gave the company a “buy” rating in a report on Thursday, December 13th. Finally, ValuEngine downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Tuesday, December 18th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Mesoblast presently has an average rating of “Buy” and a consensus price target of $13.10.

Mesoblast stock traded up $0.11 during mid-day trading on Friday, hitting $5.25. The stock had a trading volume of 83,607 shares, compared to its average volume of 77,459. Mesoblast has a one year low of $3.35 and a one year high of $8.78. The company has a market capitalization of $484.04 million, a P/E ratio of -8.33 and a beta of 1.72. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.89 and a current ratio of 2.89.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Capital World Investors bought a new position in shares of Mesoblast during the 3rd quarter valued at about $3,695,000. Penbrook Management LLC raised its position in shares of Mesoblast by 6.2% during the 4th quarter. Penbrook Management LLC now owns 240,900 shares of the company’s stock valued at $993,000 after buying an additional 14,000 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Mesoblast by 249.8% during the 3rd quarter. Renaissance Technologies LLC now owns 165,161 shares of the company’s stock valued at $1,348,000 after buying an additional 117,951 shares in the last quarter. Jane Street Group LLC raised its position in shares of Mesoblast by 590.9% during the 4th quarter. Jane Street Group LLC now owns 104,073 shares of the company’s stock valued at $426,000 after buying an additional 89,010 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Mesoblast during the 3rd quarter valued at about $215,000. 2.85% of the stock is owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Further Reading: Dividend Aristocrat Index

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.